Research Sample bioBank
Can’t find what you’re looking for? Contact us.
Or, need help ordering? 805.528.4341
Get Weekly Research Sample Updates in your Inbox:
Hepatitis C (HCV) Genotype 2 Clinical Research Samples
Discovery Life Sciences provides the highest quality Hepatitis C (HCV) Genotype 2 Clinical Research Samples and Residual Diagnostic Specimens from the Life Science Industry’s only convenient online, open access Biobank.
- All Hepatitis C (HCV) Genotype 2 Sample Orders are Packaged for Delivery within 24 Hours.
- All Specimens Ethically Obtained, De-Identified and provided with Highly Annotated Demographic and Clinical Data.
- Select from an HHS/OHRP Compliant Biorepository following ISBER/BBRB Guidelines.
- Packaged in Compliance with all UN Regulations (6.2) and U.S. DOT Hazmat regulations.
Buy | Product ID | Sample | Origin | Matrix | Vial (ml) | Quantity | Price | Age | Gender | Ethnicity | Storage Temp | Sample Date | Test 1 | Test Data 1 | Detail 1 | Test 2 | Test Data 2 | Detail 2 | Test 3 | Test Data 3 | Product Details | Price | Buy | Blood Type | Symptoms | 3-series HepB Vaccine | Is Subject on Anti-Viral Therapy / Treatment | Acquired Infection Category | Additional Testing | Hepatitis Serology | Co-Infections |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BBP0000-FG900105552020613DD | Hepatitis C (HCV) Genotype 2 | Plasma | 1.50 | 1.00 | $200.00 | 63 Y | Male | Unknown | <-70C | 06-Feb-13 | Roche TaqMan | 7,360,000 IU/mL | Innogenetics Versant HCV | 2b | $200.00 | Unknown | Fatigue | No | No | IV Drug Abuse | |||||||||||
| BBS0000-CN900105560112812DD | Hepatitis C (HCV) Genotype 2 | Egypt | Serum | 1.50 | 1.00 | $200.00 | 72 Y | Male | Unknown | <-70C | 28-Nov-12 | Bayer HCV RNA 3.0 Assay | 683,700 IU/mL | Innogenetics Versant HCV | 2 | $200.00 | Unknown | Fatigue | No | No | Unknown | ||||||||||
| BBS0000-CV900106431041014DD | Hepatitis C (HCV) Genotype 2 | Vietnam | Serum | 1.00 | 11.00 | $200.00 | 70 Y | Male | Non-Hispanic | < -70C | 10-Apr-14 | Roche cobas | 1,600,000 cps/mL | Lightpower HCV Genotype Rt-PCR | 2 | $200.00 | Unknown | Decreased appetite; Fatigue; Abdominal pain; Jaundice; Depression | No | No | Unknown | ALT: 110; AST: 68; Bilirubin: 67.3 umol/L; Serum Creatinine: 0.9 mg/dL; HCV 2009 4-Apr-14 | |||||||||
| BBS0000-CV900106441060614DD | Hepatitis C (HCV) Genotype 2 | Vietnam | Serum | 1.00 | 8.00 | $200.00 | 33 Y | Male | Non-Hispanic | < -70C | 06-Jun-14 | Roche cobas | 11,100,000 copies/mL | Lightpower HCV Genotype Rt-PCR | 2 | $200.00 | Unknown | No symptoms | No | Yes Tenofovir 300 mg; Lamivudine 150 mg; Efavirenz 600 mg | Sexual Transmission | ALT: 143; AST: 97; LDH: 203; Bilirubin: 9.8 umol/L | HBsAg-; Anti HCV+ (Elisa) | HIV+ 2013 | |||||||
| BBS0005-AA900061191101512DD | Hepatitis C (HCV) Genotype 2 | Russia | 0.5 mL Serum | 1.00 | 1.00 | $200.00 | 26 Y | Female | Unknown | < -70C | 15-Oct-12 | Abbott Realtime PCR | 480,000 IU/mL | 5-Oct-12 | Abbott Real Time PCR | 2b | 5-Oct-12 | $200.00 | Unknown | Decreased appetite, Fatigue, Depression | Yes | No | Unknown | ALT: 698; AST: 256; ALP: 112; Bilirubin: 19.0; Serum Creatinine 0.068 mg/dL 5-Oct-12 | anti HCV (G)+ (Abbott) 5-Oct-12 | ||||||
| BBS0005-CJ900061281072613DD | Hepatitis C (HCV) Genotype 2 | Italy | 0.5 mL Serum | 1.00 | 2.00 | $200.00 | 77 Y | Male | Non-Hispanic | <-70°C | 26-Jul-13 | Abbott Realtime PCR | 224 U/mL | Siemens TruGene HCV | 2a/2c | $200.00 | Unknown | Fatigue; Jaundice | No | No | Surgery | ALT: 45; AST: 65; Chronic Hepatitis | anti HCV+ (Abbott) | ||||||||
| BBS0005-CJ900075474062112DD | Hepatitis C (HCV) Genotype 2 | Italy | 0.5 mL Serum | 1.00 | 1.00 | $200.00 | 77 Y | Female | Unknown | <-70C | 21-Jun-12 | Abbott Realtime PCR | 8,890,616 IU/mL | Siemens TruGene HCV | 2a/2c | $200.00 | Unknown | Fatigue | No | No | Sexual Transmission | ALT: 15 AST: 27 ALP: 73 LDH: 325 Bilirubin: 0.71 Serum Creatinine: 1.12 mg/dL Liver Disease Diagnosis: 1999 Chronic Hepatitis 2012 | anti HCV+ (Abbott) | ||||||||
| BBS0005-CV900041872041114DD | Hepatitis C (HCV) Genotype 2 | Vietnam | 0.5 mL Serum | 1.00 | 13.00 | $200.00 | 56 Y | Male | Non-Hispanic | < -70C | 11-Apr-14 | Roche cobas | 5,320,000 copies/mL | Lightpower HCV Genotype Rt-PCR | 2 | $200.00 | Unknown | Decreased appetite; Fatigue; Abdominal pain; Jaundice; Sleep disturbances | No | No | Unknown | ALT: 40; AST: 17; ALP: 78; Bilirubin: 100 umol/L; Serum Creatinine: 1.1 mg/dL | |||||||||
| BBS0005-CV900047640091614DD | Hepatitis C (HCV) Genotype 2 | Vietnam | 0.5 mL Serum | 1.00 | 4.00 | $200.00 | 65 Y | Male | Non-Hispanic | < -70C | 16-Sep-14 | Roche cobas | 84,600 IU/mL | 5-Sep-14 | Lightpower HCV Genotype Rt-PCR | 2 | 13-Oct-14 | $200.00 | Unknown | Decreased appetite; Fatigue | No | No | Unknown | ALT: 459; AST: 1579; Bilirubin: 46.8 umol/L; Serum Creatinine: 0.8 mg/dL 3-Sep-14 | Anti HCV + (Cobas) 28-Aug-14 | ||||||
| BBS0005-CV900056189101016DD | Hepatitis C (HCV) Genotype 2 | Vietnam | 0.5 mL Serum | 1.00 | 3.00 | $200.00 | 52 Y | Male | Non-Hispanic | <-70C | 10-Oct-16 | Roche cobas | 5,030,000 IU/mL | 6-Oct-16 | Lightpower HCV Genotype Rt-PCR | 2 | 12-Oct-16 | $200.00 | Unknown | Fatigue; Abdominal pain | No | No | Unknown | ALT: 67 U/L; AST: 74 U/L; Bilirubin: 8.2 umol/L; Serum Creatinine: 86 umol/L 5-Oct-16 | Anti HCV + (cobas 6000E and Architect) 6-Sep-16 | N/A | |||||
| BBS0005-CV900069480032114DD | Hepatitis C (HCV) Genotype 2 | Vietnam | 0.5 mL Serum | 1.00 | 6.00 | $200.00 | 55 Y | Female | Non-Hispanic | < -70C | 21-Mar-14 | Roche cobas | 31,000 copies/mL | Lightpower HCV Genotype Rt-PCR | 2 | $200.00 | Unknown | Decreased appetite; Fatigue; Joint pain; Sleep disturbances | No | No | Unknown | ALT: 48; AST: 34; ALP: 74; Bilirubin: 10.2 umol/L; Serum Creatinine: 0.6 mg/dL | |||||||||
| BBS0005-EN900019495101317DD | Hepatitis C (HCV) Genotype 2 | Italy | 0.5 mL Serum | 1.00 | 10.00 | $200.00 | 60 Y | Female | Non-Hispanic | <-70C | 13-Oct-17 | Roche cobas | 3,100,000 IU/mL | 21-Sep-17 | Siemens TruGene HCV 5NC | 1b | 21-Sep-17 | HCV Date of Diagnosis | 9-Jun-10 | $200.00 | Unknown | No symptoms | No | No | U/A | ALT: 38 U/L | AST: 42 U/L | | Bilirubin: 1.35 mg/dL | Serum Creatinine: 0.26 mg/dL | Chronic Hepatitis C 5-Sep-17 | HBsAg-, HBsAb+, HBcAb-, 5-Sep-17 | None | |||
| BBS0005-EN900023466051618DD | Hepatitis C (HCV) Genotype 2 | Italy | 0.5 mL Serum | 1.00 | 2.00 | $200.00 | 55 Y | Male | Non-Hispanic | <-70C | 16-May-18 | Roche cobas | 9,560,000 IU/mL | HCV Viral Load | Genotype | 2a/2c | 10-Oct-14 | 3-series HepB Vaccine | No | $200.00 | Unknown | No symptoms | No | U/A | Bilirubin: 1.3 mg/dL | Creatinine: 1.0 mg/dL | Chronic Hepatitis C 11-May-18 | HBsAg- | HBsAb- | HBcAb- | (CMIA) 11-May-18 | None | ||||
| BBS0005-EN900023467061218DD | Hepatitis C (HCV) Genotype 2 | Italy | 0.5 mL Serum | 1.00 | 6.00 | $200.00 | 73 Y | Male | Non-Hispanic | <-70C | 12-Jun-18 | Roche cobas | 8,900 IU/mL | HCV Viral Load | Genotype | 2a/2c | 10-Oct-17 | 3-series HepB Vaccine | No | $200.00 | Unknown | No symptoms | No | Transfusion | Bilirubin: 0.63 mg/dL | Creatinine: 1.29 mg/dL | Chronic Hepatitis C 8-Mar-18 | HBsAg- | HBsAb- | HBcAb- | (CMIA) 10-Oct-17 | None | ||||
| BBS0005-EN900023469062218DD | Hepatitis C (HCV) Genotype 2 | Italy | 0.5 mL Serum | 1.00 | 10.00 | $200.00 | 76 Y | Female | Non-Hispanic | <-70C | 22-Jun-18 | Roche cobas | 627,000 IU/mL | HCV Viral Load | Genotype | 2 | 8-Jul-05 | 3-series HepB Vaccine | No | $200.00 | Unknown | No symptoms | No | U/A | Bilirubin: 0.5 mg/dL | Creatinine: 0.9 mg/dL | Chronic Hepatitis C 9-Jul-18 | HBsAg- | HBsAb- | HBcAb- | (CMIA) 18-May-18 | None | ||||
| BBS0005-EN900026484070418DD | Hepatitis C (HCV) Genotype 2 | Italy | 0.5 mL Serum | 1.00 | 1.00 | $200.00 | 68 Y | Female | Non-Hispanic | <-70C | 04-Jul-18 | Roche cobas | 9,300,000 IU/mL | HCV Viral Load | Genotype | 2 | 4-Jul-18 | 3-series HepB Vaccine | No | $200.00 | Unknown | No symptoms | No | U/A | Bilirubin: 0.6 mg/dL | Creatinine: 1.2 mg/dL | Chronic Hepatitis C 6-Jul-18 | HBsAg- | HBsAb- | HBcAb- | (CMIA) 12-Feb-18 | None | ||||
| BBS0005-EN900031760072613DD | Hepatitis C (HCV) Genotype 2 | Italy | 0.5 mL Serum | 1.00 | 1.00 | $200.00 | 60 Y | Male | Non-Hispanic | < -70C | 26-Jul-13 | Abbott RealTime PCR | 1,150,000 U/mL | Siemens TruGene HCV | 2 | $200.00 | Unknown | Fatigue | No | No | Dental Care | ALT: 135; AST: 114; ALP: 335; Bilirubin: 0.79; Serum Creatinine: 0.75 mg/dL; Chronic Hepatitis | anti HCV+ 2009 | ||||||||
| BBS0005-EN900071944092817DD | Hepatitis C (HCV) Genotype 2 | Italy | 0.5 mL Serum | 1.00 | 1.00 | $200.00 | 79 Y | Female | Non-Hispanic | <-70C | 28-Sep-17 | Roche cobas | 10,900,000 IU/mL | 28-Oct-16 | Siemens TruGene HCV 5NC | 2a | 8-May-17 | HCV Date of Diagnosis | 28-Oct-16 | $200.00 | Unknown | Fatigue | No | No | U/A | ALT: 40 U/L | AST: 40 U/L | Bilirubin: 0.5 mg/dL | Serum Creatinine: 1.0 mg/dL | Chronic Hepatitis C 11-Oct-17 | HBsAg-, HBsAb+, HBcAb+, 6-May-17 | None | |||
| BBS0005-EN900072657012318DD | Hepatitis C (HCV) Genotype 2 | Italy | 0.5 mL Serum | 1.00 | 1.00 | $200.00 | 49 Y | Female | Non-Hispanic | <-70C | 23-Jan-18 | Roche cobas | 5,430,000 IU/mL | HCV Viral Load | Genotype | 2a | 11-Nov-15 | 3-series HepB Vaccine | No | $200.00 | Unknown | No symptoms | No | U/A | ALT: 120 U/L | AST: 70 U/L | Bilirubin: 0.4 mg/dL | Creatinine: 0.5 mg/dL | Chronic Hepatitis C 22-Sep-17 | HBsAg- | HBsAb- | HBcAb- | (CMIA) 25-Oct-17 | None | ||||
| BBS0005-EN900072661020918DD | Hepatitis C (HCV) Genotype 2 | Italy | 0.5 mL Serum | 1.00 | 6.00 | $200.00 | 70 Y | Male | Non-Hispanic | <-70C | 09-Feb-18 | Roche cobas | 16700000 IU/mL | HCV Viral Load | Genotype | 2 | 10-Nov-15 | 3-series HepB Vaccine | No | $200.00 | Unknown | Fatigue | No | U/A | LDH: 161 U/L | Bilirubin: 0.4 mg/dL | Creatinine: 1.34 mg/dL | Chronic Hepatitis C 12-Feb-18 | HBsAg- | HBsAb- | HBcAb+ | (CMIA) 12-Feb-18 | None | ||||
| BBS0005-FI900061282012513DD | Hepatitis C (HCV) Genotype 2 | United States | 0.5 mL Serum | 1.00 | 3.00 | $200.00 | 57 Y | Male | Non-Hispanic | <-70°C | 25-Jan-13 | Roche cobas | 2,994,740 IU/mL | Innogenetics Versant HCV | 2 | $200.00 | Unknown | Fatigue | Yes | No | IV Drug Abuse | ALT: 155; AST: 189; ALP: 125; Bilirubin: 1.7; Serum Creatinine: 0.72 mg/dL | Hep A Total Ab-; Hep BsAg-; Hep Bc Total Ab+ |
Keep in mind that all the samples comprised in the Research Sample Biobank represent only a small number of the clinical research specimens available through our Discovery Partners™ clinical research programs. If you can’t find the specific sample type, specimen or biofluids you are looking for please make sure to call our client services group at 805.528.4341 - and ask how we can help support your project from resources available at active clinical sites.
Please read carefully before purchasing:
Clinical specimens for research use only.
Transmissible Infectious Risk! May be HIV, HBV and HCV REACTIVE or of unknown infectious agent test status. Materials provided are derived from human blood, tissue and other bio-fluids. Handle all samples as if capable of transmitting infectious agents. Practice good laboratory technique and dispose of in properly marked medical waste.
If you need help searching for a LARGER SAMPLE SET with specific data elements, please contact our Client Services group who can format Excel spreadsheets for a comprehensive review of all available samples: USA (805) 528-4341
These products are supplied without warranty for suitability for specific applications or analytical determinations.
Specimens and data will be may be used for general biomarker research, assay and instrument validation purposes only. All Research products identified as “Diagnostic Remnant Samples” are human biological materials leftover from routine laboratory analysis and are de-identified (coded) to protect subject confidentiality. Under OHRP definition 45 CFR 46.102(f) these coded specimens are not considered subjects for Human research requiring informed consent. Specimens cannot be used for whole genomic sequencing of genetic material. Research products designated as “Clinical Research Samples” by “type” are obtained from IRB approved research study protocols with informed consent obtained from each subject enrolled. Specimens cannot be used for whole genomic sequencing of genetic material.